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Coated pellets with delayed-release glucose for 
prevention of hypoglycemic episodes
Patients tend to prevent hypoglycemia by excessive saccha-
ride intake leading to poorer glycemic control with poten-
tially fatal consequences. This problem could be resolved 
by means of pellets with glucose release delayed by 120–
360 min as a compensation of the antidiabetic drug peak 
effect. No glucose is released before; hence there is no risk 
of hyperglycemia and secondary complications. The pellets 
contain glucose in combination with an osmotically active 
ingredient and are coated with an ethylcellulose disper-
sion, which forms an insoluble semipermeable membrane 
and ensures delayed release. The release of glucose was as-
sessed using dissolution and high-performance liquid 
chromatography. Dissolution profiles indicated the possi-
bility of achieving the requested lag time using a combina-
tion of adequate compositions and coating concentrations. 
Lag times of 60, 240 and 360 min were achieved. The sample 
containing carboxymethyl starch was found to be most 
suitable for the intent of this work.
Keywords: hypoglycemia, diabetes mellitus, pellets, delayed 
release, glucose, pellet evaluation
Hypoglycemia is a common, dangerous and usually unpredictable complication in 
diabetes mellitus therapy. It can be defined as the occurrence of a variety of symptoms 
associated with plasma glucose concentration lowered under 3.9 mmol/l (1, 2). If untreated, 
hypoglycemia can lead to seizures, coma, and death (3). Hypoglycemia frequently devel-
ops as a result of misbalance between the effect of insulin or peroral antidiabetics and food 
intake. Hypoglycemia during sport activities, nocturnal hypoglycemia and hypoglycemia 
caused by irregular diet are typical examples of such situations.
Children and adolescent are more vulnerable to hypoglycemia than adults. Many fac-
tors induce the risk of hypoglycemia in young patients. Children and adolescent tend to 
eat erratically and perform physical activity irregularly, making it difficult to ensure opti-
mal glucose levels during the day. Moreover, hypoglycemic symptoms may be difficult for 
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creased duration and depth of the episode. In addition, repeated hypoglycemic events can 
reduce the responses of the organism to subsequent hypoglycemic episodes, leading to 
hypoglycemia unawareness – the onset of hypoglycemia before the appearance of warning 
symptoms (4). After undergoing a severe hypoglycemic episode, children and parents try 
to prevent its recurrence by excessive intake of saccharides, which keeps blood glucose 
above the recommended values. Glycemic control is therefore poorer, which may be even 
more pernicious to patient health than a hypoglycemic episode (5). Formulation of food 
supplements with delayed release of sugar seems to be a very promising solution to this 
problem. Sugar is released after a predetermined lag time, during the peak activity of an 
antidiabetic drug. According to diabetological practice, appropriate lag times should be 
between 120–360 min, depending on the administered antidiabetic drug.
The aim of this work was to develop and evaluate a dietary supplement with con-
trolled release of carbohydrates as possible prevention of hypoglycemic episodes due to 
the imbalance between the effect of antidiabetic drugs and food intake. Such a dietary 
supplement comprises a multiparticulate delayed-release dosage form (pellets) containing 
a mixture of glucose and disintegrants or osmotically active substances coated with a 
semipermeable membrane. This allows water diffusion and consequent activation of the 
core excipients, leading to core swelling and increase in osmotic pressure. Therefore, dis-
ruptions (ruptures or punctures) are formed in the pellet coating and glucose release starts 
after a specific lag time (6). Pellets were chosen as a dosage form due to their small size that 
enables easy administration even to pediatric patients. Pellet cores were prepared using 
extrusion-spheronization and were subsequently coated in a Wurster-type fluid bed coat-
ing unit. Both pellet cores and coated pellets were evaluated for their physical character-
istics. Glucose release from coated pellets was determined by dissolution and analyzed by 
high-performance liquid chromatography. The developed compositions were originally 
extruded through a 1.0 mm mesh screen (6). Since the dietary supplement would be main-
ly intended for administration to pediatric patients, the current target was to prepare pel-




Glucose anhydrous was obtained from Dr. Kulich Pharma, Czech Republic. Micro-
crystalline cellulose (Avicel® PH 101), a mixture of microcrystalline cellulose and carboxy-
methylcellulose sodium (Avicel® RC 591), and croscarmellose sodium (Ac-Di-Sol®) were 
purchased from FMC Biopolymer, Belgium. Polyethylene glycol 6000 was acquired from 
Merck Schuchardt OHG, Germany. Carboxymethyl starch (Vivastar® P 5000) was bought 
from JRS Pharma, Germany. Aqueous ethylcellulose dispersion (Surelease® type B NF) 
was obtained from Colorcon, USA.
Preparation of cores
Pellet cores were prepared by extrusion-spheronization. Details on the composition 
of the prepared formulations are given in Table I. Dry ingredients were passed through a 
250 µm sieve and stirred in a blender (TEFAL Kaleo, Type: 676210, France) for one minute 
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at a speed of 400 rpm. Water was added and the mixture was stirred for another minute to 
ensure uniform distribution of the moistening agent in the composition. The resulting 
plastic mass was extruded through a mesh screen of 0.8 mm diameter using a screw ra-
dial extruder (Pharmex 35T, Wyss & Probst Eng, Germany). The extruded cylinders were 
collected and placed into a 230 mm cross-hatch plate spheronizer (Pharmex 35T, Wyss & 
Probst Eng, Germany). The cores were produced applying a rotation speed of 1000 rpm for 
5 minutes. The resulting cores were dried in a hot air dryer (Horo, Type 38A, Germany) at 
60 °C for 2 hours.
Coating of cores
The cores were coated with 15 % aqueous ethylcellulose dispersion (Surelease® type 
B NF) in a Wurster-type fluid bed coating unit (M-100, Medipo, Czech Republic) under the 
following conditions: spray nozzle diameter 1.0 mm, atomization pressure 1.4 bar and inlet 
air temperature 65 °C. The final coating represented 12.5, 25 or 50 % of the total pellet mass, 
resulting in three different samples for each composition. The pellets were dried in a hot 
air dryer (Horo, Type 38A, Germany) at 60 °C for 4 hours.
Evaluation of cores and coated pellets
Flow properties, i.e., flowability, bulk and tapped densities, Hausner ratio (HR), and 
Carr compressibility index (CI) were evaluated according to the European Pharmacopoeia. 
Flowability was assessed using a flow funnel with a 10 mm nozzle diameter. HR and CI 
were calculated from the values of bulk and tapped densities. Particle size and size distri-
bution were evaluated by a sieve analysis using a set of stainless steel sieves with apertures 
ranging from 0.125 to 2.000 mm (AS 200 basic, Retsch GmbH & Co. KG, Germany). Pycno-
metric density was determined in a helium pycnometer (Porotec, Pycnomatic-ATC, Ger-
many). Sphericity factor and aspect ratio were analyzed in 100 particles using an optical 
microscope (Nikon SMZ 1500, Japan) equipped with a charged coupled device camera 
(Nikon Alphaphot-2, Japan) and image analysis (Leco Instruments, Leco IA 32, USA). Core 
friability was measured by rotating in a stainless steel drum of a friabilator (Erweka TAR 
Table I. Compositions of pellets
Compound
Concentration (%, m/m)
ADS RC PEG CMS
Glucose 80.0 75.0 75.0 80.0
Avicel PH 101 15.0 – – 15.0
Ac-Di-Sol   5.0 – – –
Avicel RC 591 – 25.0 – –
PEG 6000 – – 25.0 –
CMS – – –   5.0
Watera 43.0 33.0 12.0 15.0
                                                                          a evaporates during the drying process
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10, Germany) for 10 min at 20 rpm with addition of 200 glass beads with a 4 mm diameter. 
Core moisture content was assayed in a halogen moisture analyzer (Mettler Toledo, HX204, 
Switzerland) under the following conditions: standard drying program, drying tempera-
ture 105 °C, switch-off criterion 1 mg/50 s. Scanning electron microscopy (SEM) images of 
cores and coated pellets were taken to examine the pellet shape and surface using a scan-
ning electron microscope (JCM-6000 NeoScope™ Benchtop SEM, JEOL, USA). Coating 
thickness was determined from SEM images of cut pellets as the mean diameter of four 
measurements. To obtain cut samples, single pellets were captured with a pair of tweezers, 
placed on a hard surface and cut transversely using a razor blade.
Determination of drug release
Samples of coated pellets were placed into 900 mL of water heated to 37 ± 0.5 °C for 
dissolution studies employing a dissolution apparatus (Sotax AT-7, Switzerland), basket 
method at 100 rpm. The samples were withdrawn after 60, 120, 240, 360, 540, and 720 min-
utes and subsequently analyzed for glucose content using high-performance liquid chro-
matography with an evaporative light scattering detector. Each experiment was performed 
twice and the results are expressed as mean values ± standard deviation of the active sub-
stance in % dissolved at the given sampling time.
RESULTS AND DISCUSSION
Evaluation of cores
Pellet cores should have appropriate mechanical and flow properties to enable subse-
quent coating. Produced cores were therefore tested to discern the flow properties, sphe-
ricity, aspect ratio, particle size distribution, moisture content, and friability (Table II). 
Flow character of the cores can be considered excellent when comparing the values of HR 
Table II. Physical characteristics of cores and pellets with 50 % coating
Sample Fw S AR DB DT DP HR CI M Fr CT
ADS 10.44 0.90 1.64 0.68 0.74 1.49 1.09 8.11 2.46 1.90 N/A
RC 10.46 0.88 1.71 0.75 0.81 1.50 1.08 7.41 1.03 0.24 N/A
PEG 10.59 0.83 1.85 0.71 0.75 1.43 1.06 5.33 5.19 1.12 N/A
CMS 10.50 0.83 1.89 0.77 0.82 1.51 1.06 6.10 1.18 0.51 N/A
ADS_50 11.68 0.91 1.60 0.70 0.74 1.23 1.06 5.41 N/A N/A 70.1
RC_50 11.23 0.91 1.62 0.74 0.78 1.27 1.05 5.13 N/A N/A 80.5
PEG_50 11.09 0.89 1.80 0.74 0.76 1.21 1.02 2.63 N/A N/A 66.0
CMS_50 11.06 0.83 1.81 0.72 0.76 1.26 1.06 5.26 N/A N/A 75.6
Fw – flow rate (g s–1); S – sphericity factor; AR – aspect ratio; DB – bulk density (g mL–1); DT – tapped density (g 
mL–1); DP – pycnometric density (g mL–1); HR – Hausner ratio; CI – compressibility index (%); M – moisture (%); Fr 
– friability (%), CT – coating thickness (µm).
N/A – not applicable
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and CI with the pharmacopoeial limits (7). The finding was also confirmed by the results 
of flowability evaluation. Flowability was higher than 9.5 g s–1 in all samples, which indi-
cates excellent pellet flow properties according to the literature (8). The values of pycno-
metric densities were very similar and ranged from 1.43 to 1.51 g mL–1. Results of the sieve 
analysis (Fig. 1a) revealed that the 0.50–0.80 mm fraction was most frequent in ADS, CMS, 
and PEG samples. The 0.80–1.00 mm fraction was most frequent in sample RC. The sug-
gested sphericity factor and aspect ratio for pellets is ≥ 0.8 and ≤ 1.2, respectively (9, 10). 
Although the sphericity factor met the criterion in all samples, the aspect ratio values 
showed that the core shape was not completely ideal, which was also verified by SEM im-
ages (Fig. 2). However, smaller spherical shape does not necessarily mean a complication 
since even smaller particles with more irregular shape are commonly used in pharmaceu-
tical technology (11). Core moisture content was low and ranged from 1.03 to 5.19 %. It is 
congruous to keep the residual moisture values as low as possible since higher moisture 
content might have an adverse effect on the batch-to-batch uniformity and reproducibility 
(12). When taking the value of 1.7 % as the friability limit for cores intended for subsequent 
coating, friability of RC, PEG and CMS samples was satisfactory (13). The ADS sample 
exceeded this limit only moderately and could thus be used for coating.
Fig. 1. Sieve analysis of: a) cores and b) coated pellets (50 % coating). Hatched column represents the 
ADS sample, light grey column represents the RC sample, white column represents the PEG sample 
and dark grey column represents the CMS sample.
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Evaluation of coated pellets
Pellets were evaluated again after the coating process and the evaluation results of 
cores and coated pellets were compared (Table II). Properties were evaluated only in pel-
lets with 50 % coating concentration since only small amounts of samples with 12.5 and 
25 % coating concentration were removed for the dissolution study during the coating 
process.
Coating did not have much effect on pellet shape, with sphericity and aspect ratio 
values almost the same as in cores. Pycnometric density was reduced in coated samples. 
During the coating process, density generally decreased with increasing the amount of 
Surelease® coating (14). Flowability was higher in coated samples as the coating probably 
lowered the friction and electrostatic forces between individual pellet particles. Moreover, 
coating sleeked the pellet surface, as can be seen when comparing SEM images of cores 
and coated pellets (Fig. 2 and 3). It is evident that the core structure was porous and the 
surface was smoother after the coating process. The coating layer of the individual samples 
is shown in the cut pellet images (Fig. 4). Flow character remained excellent with lower 
values of CI. Regarding particle size, it is evident that coating caused pellet enlargement 
and the major fraction drifted from 0.50–0.80 to 0.80–1.00 mm for ADS, PEG and CMS 
samples. The major fraction for sample RC was shifted to 1.00–1.25 mm (Fig. 1b). Overall, 
it can be concluded that the 50 % coating did not cause any important changes in pellet 
properties, suggesting that lower coating concentrations would have no such effect either.
In vitro glucose release
Glucose release was evaluated in pellets coated with Surelease® membrane. Sure-
lease® is an ethylcellulose dispersion pre-plasticized with dibutyl sebacate or coconut oil 
and stabilized by ammonium oleate. The membrane is insoluble, but semipermeable (15). 
Since the ethylcellulose membrane is pH-independent, the glucose release of coated pellets 
was determined in water. Water was already used as a dissolution medium for dosage 
Fig. 2. SEM images of cores.
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forms coated with ethylcellulose in various articles (16, 17). The experiment was aimed to 
examine glucose release in the stomach and small intestine. The transit time of pellets into 
these parts of the gastrointestinal tract is usually 3–7 hours (18). Longer release is thera-
peutically uninteresting and interrupted by regular diet. Therefore, the length of dissolu-
tion was set to 12 hours considering the passage of pellets through the gastrointestinal 
tract and the required length of lag time. Longer dissolution times would be suitable for 
studying glucose release in the colon (19). One dissolution profile was acquired for each 
coating level, resulting in three different profiles for each composition (Fig. 5).
In general, it can be taken that 12.5 % ethylcellulose coating was not suitable for the 
purpose of this work since the glucose release was immediate in all cases. No lag time was 
Fig. 3. SEM images of coated pellets.
Fig. 4. SEM images of cut pellets. Standard numbers identify the coating thickness, underlined num-
bers identify the total pellet length.
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observed in 25 % concentrations in ADS and RC samples either. Lag times achieved in PEG 
and CMS samples were too short for the purposes of this work (60 min). As observed pre-
viously, lag time is represented by the period when the coating is intact and the length of 
this period is usually based on the coating thickness. The glucose release starts with the 
formation of coating disruptions (punctures or ruptures) (6). These disruptions develop 
too early in lower coating concentrations, which is therefore insufficient for the purposes 
of this work.
Considering the 50 % coating concentration, the glucose release was delayed in all 
samples with lag times either 240 (ADS) or 360 min (RC, PEG, CMS). Nevertheless, the 
amount of released glucose was extensively lowered compared to samples with 12.5 and 
25 % coating concentrations. The only exception was the CMS sample where the amount 
of glucose released after the desired lag time was evidently higher than in other samples. 
Accordingly, it can be presumed that carboxymethyl starch demonstrated the highest 
swelling ability and water sorption ratio of the excipients used. As water is absorbed into 
the interior of particle pores, polymer chains expand into a three-dimensional network in 
which water is retained. Large three-dimensional swelling of carboxymethyl starch par-
Fig. 5. Dissolution profiles of glucose pellets with different composition and coating concentration. 
The full line (——) represents 12.5 % coating, the dashed line (– – –) represents 25 % coating, and the 
dash-dot line (– ∙ –) represents 50 % coating.
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ticles was reported, whereas another superdisintegrant, croscarmellose sodium, is able to 
swell in three dimensions only partially and its swelling ability is therefore lower (20). 
Slow release in the PEG sample may be attributed to the osmotic effect of polyethylene 
glycol, which is probably less effective in higher coating concentrations than the swelling 
ability of disintegrants. Carboxymethyl cellulose in the RC sample probably slowed down 
glucose release due to the formation of a gel structure in the initial stages of dissolution 
(21).
Relations between the compositions, coating concentrations and amounts of released 
glucose were assessed. In general, increasing coating concentration prolonged the lag 
time, but extensively lowered the amount of released glucose (ADS, RC, and PEG samples). 
Considering the dissolution profiles of the CMS sample, the lag time was prolonged from 
60 min (25 % coating) to 360 min (50 % coating), with a sufficient amount of released glu-
cose. It can be assumed that these lag times would also be reached in vivo, since glucose 
release from the samples containing carboxymethyl starch is unaffected by the change of 
pH (22). This suggests that the pellet composition containing carboxymethyl starch is most 
suitable for the intention of this work and for future use. Therefore, more lag times in the 
required interval could be presumably achieved by using the same composition and coat-
ing concentrations in the 25–50 % range.
CONCLUSIONS
A dietary supplement for hypoglycemia prevention was successfully prepared in the 
form of coated pellets with delayed release of glucose. The resulting pellets, which release 
glucose at clinically suitable time intervals, may be mixed with semi-solid or liquid food 
or dispersed in a beverage and ingested together with food. Therefore, the patient can 
administer the dietary supplement a few hours before possible hypoglycemia, e.g., prior to 
prolonged physical activity or before bedtime. The elevated demand of glucose is subse-
quently saturated after a defined lag time. In general, it can be concluded that the lag time 
length is affected not only by the coating concentration, but also by the core composition. 
Accordingly, the requested lag times can be achieved by a combination of adequate coating 
concentration and composition. Based on the dissolution profiles, the CMS sample seems 
to be the most appropriate composition, meeting the basic requirements for the dosage 
form aimed to prevent hypoglycemia. It can be assumed that pellets with coating concen-
trations in the range of 25–50 % will probably also release glucose after the desired time 
interval (120–360 min) and this, along with verifying the results in vivo, could be the scope 
of further experiments.
Abbreviations. – ADS –croscarmellose sodium, CI – Carr compressibility index, CMS –carboxy-
methyl starch, HR – Hausner ratio, PEG –polyethylene glycol, RC –Avicel® RC 591, SEM – scanning 
electron microscopy.
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tion of a dosage form with controlled release of glucose for the prevention of hypoglycemic states.
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